

**From:** dph.immunizations@ct.gov <noreply@everbridge.net>  
**Sent:** Monday, January 8, 2024 1:34 PM  
**Subject:** Nirsevimab Supply Update and COCA Guidance 01.08.2024



DEPARTMENT OF PUBLIC HEALTH

[Please click here to acknowledge receipt of this message](#)

**January 8, 2024**

*This communication is being sent to all key contacts at provider organizations enrolled in the CT Vaccine Program (CVP). Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our web site [here](#).*

Dear CVP providers,

The Centers for Disease Control and Prevention (CDC) recently notified the State Immunization Program that we will be receiving **up to** an additional 1,795 doses of the 50mg nirsevimab vials and 250 doses of the 100mg vials during the remainder of the 2023–2024 RSV season. We have not yet received these doses in our allocation, but expect to receive them anytime during the next few weeks.

### **Nirsevimab Orders**

**Since it has been several weeks to months since orders began for nirsevimab, we ask that all providers who need doses please place a new order; we will disregard orders placed prior to today, 1/8/2024.**

Please place nirsevimab orders using this [link](#). Other vaccines not on allocation should continue to be placed in CT WiZ as usual. At this time there are no nirsevimab orders out for delivery so if you have not received doses you ordered prior to today, you can consider those orders canceled.

We will continue to prioritize vaccine orders placed by birth hospitals, and fill orders from other healthcare settings with any doses remaining. We plan to fill orders to the best of our ability when an allocation is provided, and not save doses for providers who have not yet placed an order (i.e. we will not hold on to doses for birth hospitals).

If you received nirsevimab through the CVP and will not be able to use all of the vials received this season, please contact the Immunization Program at [immi.dph@ct.gov](mailto:immi.dph@ct.gov) or your local birth hospital to inquire about redistribution of doses.

## **CDC's COCA Guidance Update January 5, 2024**

### **Summary**

On October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued Health Alert Network (HAN) [Health Advisory 499](#) to provide guidance for prioritization of nirsevimab given limited supply. Nirsevimab (Beyfortus, Sanofi and AstraZeneca) is a long-acting monoclonal antibody immunization recommended for preventing RSV-associated lower respiratory tract disease in young children.

Given the recent increase in nirsevimab supply and the [manufacturers' plan to release an additional 230,000 doses in January](#), CDC advises healthcare providers to return to recommendations put forward by CDC and the [Advisory Committee on Immunization Practices \(ACIP\)](#) on use of nirsevimab in young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible.

Healthcare providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower. RSV activity remains elevated nationwide and is continuing to increase in many parts of the country, though decreased activity has been observed in the Southeast.

**Full statement available here: [COCA Now: January 5, 2024: Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus \(RSV\) during the 2023–2024 Respiratory Virus Season](#)**

**For the CT DPH Immunization Program, visit: [Contact Us](#)**

We understand the challenges providers now face with the limited supply of nirsevimab. We are working with the CDC to advocate for as many doses as possible to come to Connecticut.

*If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).*